Sponsored Videos

A panelist discusses how intranasal epinephrine could revolutionize anaphylaxis management by overcoming barriers such as needle anxiety, delayed administration, and underuse—especially in pediatric and high-risk groups—through its needle-free, user-friendly design, rapid and effective drug delivery, longer shelf life, and temperature stability; coupled with the critical importance of early epinephrine use, updated guidelines, and shared decision-making, this innovation promises to improve patient outcomes by enhancing accessibility, caregiver confidence, and adherence while addressing practical issues like cost and education.

The content of this program has been supported by ARS Pharmaceuticals

The content of this program has been supported by DermaSensor

Panelists emphasize the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, addressing access and diagnostic challenges, managing patient concerns, and ensuring proper use and billing of new technologies to improve outcomes.

Sakina S. Bajowala, MD,discusses how intranasal epinephrine (Neffy) offers a needle-free alternative to auto-injectors for treating anaphylaxis, addressing barriers like needle phobia and improper injection while demonstrating comparable efficacy and safety to traditional intramuscular epinephrine devices.

The content of this program has been supported by ARS Pharmaceuticals

Amar Dixit, MD, MBA, FACAAI, FAAAI discusses how intranasal epinephrine (Neffy) presents an effective alternative to traditional autoinjectors for anaphylaxis treatment, addressing key barriers like needle phobia, device portability, and storage constraints while demonstrating comparable or superior pharmacokinetic and physiological responses to intramuscular delivery methods.

The content of this program has been supported by ARS Pharmaceuticals

Todd W. Frieze, MD, discusses the therapeutic role of TSH suppression in differentiated thyroid cancer, as well as treatment goals and ongoing surveillance strategies.

Alex Tessnow, MD, reviews the presentation of hypothyroidism among elderly patients and outlines key considerations for treatment.

Experts share an overview of IBS-C and CIC in adult patients and explore solutions for addressing the challenges leading to treatment discontinuation. They also discuss the impact of variable onset of individual abdominal and bowel symptom response, as well as the role of adverse effects on treatment adherence in patients with IBS-C and CIC. And finally, they review strategies for setting treatment expectations and highlight the importance of an effective patient-provider relationship and optimizing long-term clinical outcomes for these chronic conditions.

An expert in the management of hypothyroidism shares valuable insights on effective patient communication. She emphasizes the non-specific nature of symptoms and underscores the significance of treatment compliance in goal setting. Additionally, she discusses the factors affecting TSH values and highlights the narrow therapeutic range of thyroid medication, with an emphasis on proper administration.